LAG3 and non-small cell lung carcinoma: The current study, NEOpredict-Lung, aims to establish the feasibility of combining the PD-1 blocking antibody, nivolumab, and the LAG-3 blocking antibody, relatlimab, in preoperative treatment of NSCLC patients.